Duopharma Biotech BhdXKLS:7148 +2.46%82 Return-on-Tangible-Equity is 17.04% as of Mar. 2026, which is 63% above its 10-year median of 10.43. GuruFocus rates XKLS:7148 with a GF Score™ of 82/100 and a GF Value™ of RM1.53 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 897 Drug Manufacturers companies, Duopharma Biotech Bhd ranks better than 66.33% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Duopharma Biotech Bhd's annualized net income for the quarter that ended in Mar. 2026 was RM122.9 Mil. Duopharma Biotech Bhd's average shareholder tangible equity for the quarter that ended in Mar. 2026 was RM721.1 Mil. Therefore, Duopharma Biotech Bhd's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 17.04%.
The historical rank and industry rank for Duopharma Biotech Bhd's Return-on-Tangible-Equity or its related term are showing as below:
XKLS:7148'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 6.08 Med: 10.43 Max: 13.19
Current: 13.19
During the past 13 years, Duopharma Biotech Bhd's highest Return-on-Tangible-Equity was 13.19%. The lowest was 6.08%. And the median was 10.43%.
XKLS:7148's Return-on-Tangible-Equity is ranked better than 66.33% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs XKLS:7148: 13.19
Duopharma Biotech Bhd (XKLS:7148) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Duopharma Biotech Bhd Return-on-Tangible-Equity Related Terms
Duopharma Biotech Bhd Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Duopharma Biotech Bhd's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duopharma Biotech Bhd Return-on-Tangible-Equity Chart
XKLS:7148 vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 17.04% mean?
Duopharma Biotech Bhd (XKLS:7148) has a Return-on-Tangible-Equity of 17.04% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Duopharma Biotech Bhd and its competitors. This is 63% above median its historical median of 10.43. Over the past decade, Duopharma Biotech Bhd's Return-on-Tangible-Equity has ranged from 6.08 to 13.19. According to the industry distribution chart, Duopharma Biotech Bhd ranks #302 out of 897 companies in the Drug Manufacturers industry, placing it in the top 33.7%.
Is Duopharma Biotech Bhd's Return-on-Tangible-Equity too high?
Duopharma Biotech Bhd's current Return-on-Tangible-Equity of 17.04% is 63% above median its 10-year median of 10.43. Over the past 10 years, this metric has ranged from a low of 6.08 to a high of 13.19. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Duopharma Biotech Bhd's value of 17.04% is 115.7% above this industry median. Based on the distribution chart, Duopharma Biotech Bhd ranks #302 out of 897 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Duopharma Biotech Bhd has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #302 out of 897 companies for Return-on-Tangible-Equity. This puts Duopharma Biotech Bhd in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Duopharma Biotech Bhd's value of 17.04% is 115.7% above this benchmark. Historically, Duopharma Biotech Bhd's own Return-on-Tangible-Equity has ranged from 6.08 to 13.19 over the past decade. While the company's 10-year median is 10.43 vs. the industry median of 7.90, Duopharma Biotech Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current Return-on-Tangible-Equity of 17.04% is 115.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current Return-on-Tangible-Equity is 17.04%, which is 63% above median its own 10-year median of 10.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.53, compared to a current price of RM1.25 — trading 18.3% below its estimated fair value. The current Return-on-Tangible-Equity is 17.04%, which is 63% above median its 10-year median of 10.43 and 115.7% above the Drug Manufacturers industry median of 7.90. Duopharma Biotech Bhd's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Return-on-Tangible-Equity is 17.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.25 is trading 18.3% below its estimated GF Value™ of RM1.53.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
Return-on-Tangible-Equity: 17.04% (63% above median its 10-year median of 10.43)
GF Value™: RM1.53 vs. price of RM1.25 (18.3% below fair value)
Industry Position: 115.7% above the Drug Manufacturers median (#302 of 897)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
82GF Score
Get the complete analysis for XKLS:7148
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
